Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839111 | 0.83 | NPC1 (0.49) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5999076 | 0.79 | TACR1 (0.54) | RAB9ANPC1SMN1; SMN2OPRM1 | |
| SCHEMBL5997623 | 0.79 | SLC6A9 (0.51) | RAB9ANPC1SMN1; SMN2CYP2C9MEN1 | |
| SCHEMBL5997782 | 0.78 | RAB9A (0.47) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5998358 | 0.77 | HPGD (0.58) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31530573 | 0.77 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL6838166 | 0.76 | HPGD (0.51) | CYP1A2CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL5998832 | 0.76 | TACR1 (0.66) | — | |
| SCHEMBL28928814 | 0.74 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL5997936 | 0.73 | ALDH1A1 (0.51) | RAB9ACYP2C9CYP2C19KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103217-A1 | Anti-inflammatory compounds | SCOTT MALCOLM K (US) | 2002-08-01 | — | — | US | claimed |
| US-6372779-B1 | ANTHRACENE DERIVATIVES WITH CARBAMOYL GROUPS, AMIDO GROUPS, UREA GROUPS AND SULFONAMIDE GROUPS | ORTHO PHARMACEUTICAL CORPORATION | 2002-04-16 | — | — | US | claimed |
| EP-0966430-A1 | ANTI-INFLAMMATORY COMPOUNDS | Ortho-Mcneil Pharmaceutical Corp. (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1999033786-A1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION (US) | 1999-07-08 | — | — | WO | claimed |
| US-7141674-B2 | Anti-inflammatory compounds | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040082601-A1 | Anti-inflammatory compounds | SCOTT MALCOLM K (US) | 2004-04-29 | — | — | US | disclosed |
| US-20030171585-A1 | Triphenylpropanamide compounds | SCOTT MALCOLM K (US) | 2003-09-11 | — | — | US | disclosed |
| US-6509369-B2 | Triphenylpropanamide compounds; useful in treating inflammations but which do not demonstrate side effects associated with other anti-inflammatory treatments such as glucocorticoids | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020103217-A1 | Anti-inflammatory compounds | SCOTT MALCOLM K (US) | 2002-08-01 | — | — | US | disclosed |
| EP-0966430-B1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO MCNEIL PHARM INC (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6372779-B1 | ANTHRACENE DERIVATIVES WITH CARBAMOYL GROUPS, AMIDO GROUPS, UREA GROUPS AND SULFONAMIDE GROUPS | ORTHO PHARMACEUTICAL CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-0966430-A1 | ANTI-INFLAMMATORY COMPOUNDS | Ortho-Mcneil Pharmaceutical Corp. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999033786-A1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082601-A1 | Anti-inflammatory compounds | TNF, PTGES, PTGES2 | RAB9A 3661/4885NPC1 1491/4885SMN1; SMN2 4242/4885 |
| US-20030171585-A1 | Triphenylpropanamide compounds | PTGES, PTGES2, MPO | RAB9A 3374/4885NPC1 1914/4885SMN1; SMN2 3101/4885 |
| US-20020103217-A1 | Anti-inflammatory compounds | TNF, PTGES, PTGES2 | RAB9A 3661/4885NPC1 1491/4885SMN1; SMN2 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.